Hot Investor Mandate 3: Europe-Based Firm Invests In Next Wave Life Science Technologies

1 Mar

An investment firm based in Spain raised a EUR 200 million fund to make stage agnostic life science deals, investing from early stages to pre-IPO. The firm prefers to lead rounds, particularly in late-stage opportunities. The firm is currently focused on opportunities in Europe. The firm may syndicate international opportunities with US investors. The firm typically reserves EUR 12-15 million per portfolio company.

The firm invests opportunistically in next wave healthcare technologies, including therapeutics, digital health, and medical devices. The firm will also consider diagnostic opportunities on occasion. The firm will invest at any stage of development.

The firm invests globally, but focuses on Europe and prefers to invest in companies with a Spain angle, such as IP or founders from Spain.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

%d bloggers like this: